ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1163

Characteristics of Interstitial Lung Disease Progressors in an Antisynthetase Autoantibody-Positive Population

Aurélie Mourot1, Beatrice Panuta1, Juliette Charbonneau1, Ange Mounkam Ngeuleu1, Caroline Vo2, Eric Rich3, Josiane Bourré-Tessier3, Edith Villeneuve3, Hélène Manganas3, Andréanne Gauthier3, Julie Morisset3, Sabrina Anh-Tu Hoa3 and Océane Landon-Cardinal3, 1University of Montreal, Montreal, QC, Canada, 2Hôpital Charles Lemoyne, Montreal, QC, Canada, 3Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, interstitial lung disease, Myositis, OMERACT, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Antisynthetase syndrome (ASSD) is characterized by interstitial lung disease (ILD), myositis, polyarthritis, Raynaud’s phenomenon, dermatomyositis-like rash and mechanic’s hands. ILD may present with isolated antisynthetase-specific autoantibodies (AS-aAbs) without other ASSD features. The objective was to compare the characteristics and evolution of patients with ILD and AS-aAb with and without systemic manifestations of ASSD.

Methods: Patients evaluated at the ILD Clinic with AS-aAb detected by line blot assay (Euroimmun) were included. Patients were classified as ASSD if they had at least 1 other systemic manifestation(s) of ASSD, and otherwise as interstitial pneumonia with autoimmune features (IPAF) and non-IPAF according to 2015 ERS/ATS criteria. ILD progression was defined as meeting ATS/ERS/JRS/ALAT or OMERACT criteria, need for oxygen supplementation or lung transplant, or death. Time to ILD progression was analyzed using Kaplan-Meier and multivariable Cox analyses.

Results: Sixty-eight patients were included (12 ASSD, 13 IPAF, 43 non-IPAF). Most common AS-aAbs were anti-PL7/12 (71%). Mean age was 67 years, 69% were male, 87% were Caucasian and median follow-up was 2.4 [0.5,4.9] years. ASSD patients more frequently had concomitant anti-Ro52-aAbs (40% vs 5%, p=0.0004) and moderate-strong titers of AS-aAbs (60% vs 23%, p=0.004). Non-IPAF patients more frequently presented with usual interstitial pneumonia (UIP) pattern (64% vs 16%, p=0.0005) and were numerically more often male (74% vs 60%) with a smoking history (88% vs 68%) and moderate-severe ILD (56% vs 29%) on high-resolution CT scan. Antifibrotics were mainly used in non-IPAF patients (43% vs 4%, p=0.0006). Upon follow-up, 31 of 55 (56%) and 36 of 64 (56%) patients experienced ILD progression using ATS and OMERACT criteria, respectively. Unadjusted Kaplan-Meier analyses showed a protective association between ASSD/IPAF and ILD progression (HR 0.38, 95% CI: 0.19-0.78, p=0.008 using ATS; HR 0.47, 95% CI: 0.24-0.91, p=0.03 using OMERACT, see Figure). Multivariable Cox analyses showed that male sex was an independent predictor of ILD progression, and that non-IPAF and UIP pattern were numerically associated with increased risk (see Table). After multidisciplinary assessment, non-IPAF patients were ultimately diagnosed with idiopathic interstitial pneumonia (IPF) in 56%, non-classifiable in 30%, hypersensitivity pneumonitis in 10%, sarcoidosis in 2% and smoking-related ILD in 2% of cases.

Conclusion: In this AS-aAb-positive population, ILD progression was more frequent in men with UIP pattern irrespective of ASSD, IPAF and non-IPAF classification. Most non-ASSD patients in our cohort did not fulfill IPAF criteria and were ultimately diagnosed as IPF. Further study is required to identify predictors of progression while accounting for treatment effect and confounding by indication. Future classification criteria for ASSD should consider the reliability of AS-aAb detection using different methods.

*Drs Landon-Cardinal and Hoa contributed equally to this abstract.

Supporting image 1

Figure: Kaplan-Meier curves for risk of ILD progression using A) ATS (p=0.008) and B) OMERACT (p=0.03) criteria

Supporting image 2

Table: Risk factors for ILD progression using multivariable Cox analyses


Disclosures: A. Mourot: None; B. Panuta: None; J. Charbonneau: None; A. Mounkam Ngeuleu: None; C. Vo: None; E. Rich: None; J. Bourré-Tessier: None; E. Villeneuve: None; H. Manganas: None; A. Gauthier: None; J. Morisset: None; S. Anh-Tu Hoa: None; O. Landon-Cardinal: None.

To cite this abstract in AMA style:

Mourot A, Panuta B, Charbonneau J, Mounkam Ngeuleu A, Vo C, Rich E, Bourré-Tessier J, Villeneuve E, Manganas H, Gauthier A, Morisset J, Anh-Tu Hoa S, Landon-Cardinal O. Characteristics of Interstitial Lung Disease Progressors in an Antisynthetase Autoantibody-Positive Population [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/characteristics-of-interstitial-lung-disease-progressors-in-an-antisynthetase-autoantibody-positive-population/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characteristics-of-interstitial-lung-disease-progressors-in-an-antisynthetase-autoantibody-positive-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology